Study of Difluprednate in the Treatment of Uveitis

The purpose of this study is to determine the safety and efficacy of difluprednate compared with prednisolone acetate in the treatment of endogenous anterior uveitis.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Uveitis Eye Diseases Uveal Diseases

Age range

2 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

John-Kenyon American Eye Institute

New Albany, Indiana, 47150, United States

Who can participate

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Diagnosis of endogenous anterior uveitis in at least 1 eye

Exclusion criteria

Presence of intermediate uveitis, posterior uveitis or panuveitis
Corneal abrasion
Any confirmed or suspected active viral, bacterial, or fungal keratoconjunctival disease
Allergy to similar drugs, such as other corticosteroids

Treatment and study plan

Difluprednate

Drug

Prednisolone Acetate

Drug

Sponsors and collaborators

Lead sponsor

Sirion Therapeutics, Inc.

Industry

Registry information

Important dates

First posted: Jul 16, 2007
Registry last updated: Aug 29, 2008

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed